Interferon (IFN)-b induces S-phase slowing and apoptosis in human papilloma virus (HPV)-positive cervical carcinoma cell line ME-180. Here, we show that apoptosis is a consequence of the S-phase lengthening imposed by IFNb, demonstrating the functional correlation between Sphase alteration and apoptosis induction. In ME-180 cells, where p53 function is inhibited by HPV E6 oncoprotein, IFN-b effects on cell cycle and apoptosis occur independently of p53. The apoptosis due to IFN-b is mediated by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in a manner dependent on the S-phase deregulation. IFN-b appears to increase TRAIL expression both directly at the mRNA level and indirectly by augmenting surface protein levels as a consequence of the induced S-phase cell accumulation. Moreover, the alteration of the S-phase due to IFN-b promotes TRAILdependent apoptosis by potentiating cell sensitivity to TRAIL, possibly through induction of a proapoptotic NFjB activity and TRAIL-R2 receptor expression. Interestingly, IFN-b-induced TRAIL-dependent apoptotic events strongly differ in the requirement of caspase activity. These results show that IFN-b may induce an apoptotic response by deregulating cell cycle. Understanding the linkage between these mechanisms appears to be of primary importance in the search for new IFN-based therapeutic strategies to circumvent cancer disease or improve clinical outcome.
Introduction
There is accumulating evidence that cell cycle deregulation may prevent or induce an apoptotic response depending upon the cellular context (Pucci et al., 2000) . In mammalian cells, apoptosis can be initiated through the engagement of the death receptors, and/or the release of cytochrome c from the mitochondria. The death receptor pathway is initiated by the tumor necrosis factor (TNF) family of cytokines, such as TNFa, Fas-ligand and TNF-related apoptosis-inducing ligand (TRAIL)/APO-2L, all of which can act as extracellular activators of apoptosis upon binding to their respective receptors (Armitage, 1994) . These receptors recruit adapter proteins such as FADD, which in turn bind caspase-8 molecules, resulting in caspase-8 activation. Caspase-8 directly activates caspase-3 or acts by cleaving Bid, a member of Bcl-2 family, which targets mitochondria for cytochrome c release (Scaffidi et al., 1998; Stennicke et al., 1998; Gross et al., 1999) .
TRAIL induces apoptosis in various tumor cells without affecting normal cells; therefore, it is a promising candidate for cancer therapy (Fiorucci et al., 2005) . At least four receptors bind to TRAIL with similar affinity. Both TRAIL-R1/DR4 and TRAIL-R2/ DR5 recruit caspase-8 or -10 via FADD and activate the caspase cascade, resulting in apoptotic cell death. In contrast, TRAIL-R3 and TRAIL-R4 seem to work as decoy receptors (Baetu and Hiscott, 2002) . TRAIL-R3 lacks a cytoplasmic domain and exists as a glycophospholipid-anchored protein on the cell surface; TRAIL-R4 carries a cytoplasmic-truncated death domain that cannot transmit a death signal. The physiological functions of these multiple TRAIL-Rs remain obscure. Binding of TRAIL to TRAIL-R1 and TRAIL-R2 leads also to the activation of NF-kB by a TRAF2-NIKIKKa/b-dependent signaling and c-Jun N-terminal kinase (Hu et al., 1999; Muhlenbeck et al., 2000) . NFkB can also be activated through TRAIL-R4. The role of NF-kB is poorly characterized and appears to be dependent on the cellular type. The possible induction of NF-kB-dependent antiapoptotic activities by TRAIL, supposed to underlie the resistance of normal cells to TRAIL, is consistent with the observation that repression of NF-kB function by some chemotherapeutic agents (Ghosh et al., 2003) or interferon (IFN)-b (Shigeno et al., 2003) can enhance TRAIL-mediated cancer cell death. In contrast, it has been shown that TRAIL-dependent NF-kB activation triggers apoptosis in T cells and epithelial cell lines by inducing proapoptotic genes (Baetu et al., 2001; Shetty et al., 2002) .
IFNs exert both antiviral and antitumor effects and have been clinically used for treatment of viral infections as well as malignancies, alone or in combination with other chemotherapeutic drugs (Borden et al., 2000) . Both type I and II IFNs act through cell-membrane receptors and JAK/STAT signaling pathways to regulate the expression of a large set of genes. Some of the IFN-induced genes are associated with apoptosis. It has been shown that IFN-a/b stimulates the expression of TRAIL in T-lymphocytes or dendritic cells (Fanger et al., 1999; Kayagaki et al., 1999) , and the apoptosis observed in several cancer cells susceptible to IFN-a/b is mediated by induction of endogenous TRAIL (ChawlaSarkar et al., 2001; Chen et al., 2001; Toomey et al., 2001; Choi et al., 2003) . Moreover, type I and II IFNs can promote TRAIL-dependent apoptosis by upregulating TRAIL-R1 and/or TRAIL-R2 receptors in several cell lines (Sedger et al., 1999; Meng and El-Deiry, 2001; Shigeno et al., 2003) . However, the link between IFNinduced gene expression and cell death is still poorly elucidated and appears to be strictly dependent on cellular context. The characterization of the specific IFN-induced signals that promote apoptosis is essential to identify novel pharmacological targets useful to augment tumor cell death in cancer therapy.
We reported that type I IFNs inhibit cell proliferation and induce apoptotic cell death in human papilloma virus (HPV)-positive cervical squamous cell carcinoma (SCC) lines (Giandomenico et al., 1998) . More recently, we demonstrated that IFN-b affects cell growth of SCC lines by inducing a significant lengthening of the cell cycle S-phase (Vannucchi et al., 2000) . In the present study, we define the mechanisms of IFN-negative control of cell growth in ME-180 SCC cells. We report that S-phase lengthening imposed by IFN-b triggers apoptotic cell death. The apoptotic process is mediated by TRAIL, whose expression is induced by IFN-b. The alteration of S-phase promotes TRAIL-dependent apoptosis by increasing surface TRAIL levels and potentiating cell sensitivity to TRAIL through induction of NF-kB activity and TRAIL-R2 expression. Interestingly, the observed apoptotic events strongly differ in the requirement of caspase activation, suggesting the involvement of both caspase-dependent and -independent pathways.
Results

IFN-b-induced S-phase slowing is associated with apoptotic cell death
To assess if the cell cycle S-phase lengthening induced by IFN-b could cause the apoptotic death observed in SCC cell lines, ME-180 cells were incubated with IFN-b and analysed for cell cycle distribution and apoptosis induction. Apoptosis was detected by Annexin-V/ Hoechst double staining to relieve phosphatidylserine (PS) externalization and nuclear morphology, and by in situ detection of caspase activity through incubation with a fluorescent broad-spectrum caspase inhibitor. Figure 1 shows that apoptosis induction is consistent with the kinetics of cell accumulation in the S-phase. Annexin-V/Hoechst combined analysis together with Annexin-V/PI double staining (data not shown) allowed us to consider Annexin-V positiveness representative enough of the entire apoptotic population in this cell system, PS externalization being a common feature of both early and late apoptotic stages. It is important to note that although the percentage of apoptotic cells does not appear very high, it can significantly affect population survival, since cell cycle progression is strongly inhibited. In fact, cell proliferation is reduced by 92% (72.5 s.d.) after 6 days of IFN-b treatment. As expected, S-phase slowing and apoptosis induction were also observed by using IFN-a at higher doses (data not shown), according to its lower antiproliferative potential in SCC lines (Giandomenico et al., 1998) .
In agreement with our previous observations (Giandomenico et al., 1998) , the IFN-b-induced apoptosis in ME-180 cells appeared to be strongly associated with cell detachment, since no significant numbers of apoptotic cells were detected in the adherent populations, whereas more than 90% of floating cells were Annexin-V positive (data not shown).
Apoptosis is a consequence of the IFN-b-induced S-phase slowing
To investigate the relationship between S-phase lengthening and apoptotic cell death, we assessed whether the IFN-b-induced apoptosis could be prevented by blocking cell cycle progression through the S-phase. ME-180 cells were treated for different periods with the DNA synthesis inhibitor aphidicolin alone or in combination with IFN-b. As shown in Figure 2a , all populations were similarly arrested in the early S-phase. The addition of IFN-b did not result in an increase of apoptotic cells at all time points, indicating that apoptosis could be a consequence of the IFN-b-induced S-phase alteration. To corroborate this point, ME-180 cells were synchronized in the early S-phase by aphidicolin -with or without IFN-b -and then released in cell cycle in the presence or not of IFN-b. In synchronized cells, apoptosis induction by IFN-b was significantly higher than in asynchronous samples, according to a stronger accumulation of cells in the S-phase (Figure 2b) . Altogether, these results support a functional correlation between IFN-b-induced S-phase alteration and apoptotic cell death.
S-phase deregulation and apoptosis induction by IFN-b are independent of p53
We have previously observed that IFN-b-induced Sphase slowing is associated with PML upregulation (Vannucchi et al., 2000) . Since the HPV-positive ME-180 cell line expresses the viral oncoprotein E6, known to inhibit p53, we evaluated whether IFN-b could exert its effect on cell cycle and apoptosis by activating p53 via PML upregulation. We generated clones of ME-180 cells overexpressing the mutant protein p53His175, acting as a dominant negative of endogenous wt-p53 protein (Blandino et al., 1999) . Two of the strongest p53His175-positive clones (ME-180-dnp53#1 and ME-180-dnp53#38) and one control clone (ME-180-puro#2) were transiently transfected with the p53 responsive MDM2-Luciferase construct and treated with As 2 O 3 , as p53 inducer, to evaluate the inhibition of the endogenous wt-p53. In spite of a significant inhibition of p53 transactivation function (Figure 3a ), dnp53-expressing clones did not differ from parental cells in response to IFN-b, either in S-phase lengthening or in apoptosis induction (Figure 3b and c) , confirming that p53 transcriptional activity is not principally involved in the antiproliferative effect of IFN-b on ME-180 cells.
IFN-b-induced apoptosis is mediated by TRAIL
To identify the molecular determinants of the IFN-binduced apoptosis, asynchronous and synchronized ME-180 cells were incubated with IFN-b for 48 h, and the mRNA levels of 205 genes involved in cell cycle and apoptosis regulation were evaluated through macroarray analysis. TRAIL mRNA appeared significantly upregulated by IFN-b in both experimental conditions (Figure 4a ). A few other gene products were weakly increased by IFN-b, most of which according to the presence of a larger amount of apoptotic cells in synchronized populations. RNase protection assay indicated that TRAIL mRNA is induced as early as 6 h upon IFN-b treatment and increases with time to a similar extent in asynchronous and synchronized cells (data not shown).
To evaluate if apoptosis induced by IFN-b, as a consequence of the S-phase deregulation, was essentially dependent on TRAIL death signaling, we used soluble DR5 (TRAIL receptor 2) to impair TRAIL activity. Figure 4b shows that recombinant DR5 inhibited the apoptosis due to IFN-b, whereas a neutralizing anti-Fas TRAIL is expressed as a characteristic type II transmembrane protein and in small proportion as a soluble form. Interestingly, by using FITC-conjugated TRAIL-R2, we observed that IFN-b increased surface TRAIL levels overall in synchronized cells. To value whether the S-phase accumulation per se could augment TRAIL expression on cell membrane, we analysed surface TRAIL in synchronous ME-180 cells progressing through the different cell cycle phases. We found that TRAIL basal levels were cell cycle dependent, being greater in S and G2 phases ( Figure 4c ). It is important to note that in IFN-b-treated synchronized samples, where the total percentage of cells in S and G2 phases was about 60%, TRAIL expression value exceeded that relieved in the untreated population composed by more than 90% of cells in the S-phase (middle S-phase sample). Thus, IFN-b significantly upregulates TRAIL both directly at mRNA level and indirectly through the S-phase cell accumulation.
IFN-b affects TRAIL signaling by increasing NF-kB activity and TRAIL-R2 receptor expression
Besides caspase cascade, TRAIL can also activate NF-kB, possibly regulating the expression of both antiapoptotic and proapoptotic factors (Wang et al., 1998; Chen et al., 2000; Baetu et al., 2001; Shetty et al., 2002) . IFN-a/b is able to sensitize different cell types to TRAIL-induced apoptosis by repressing survival functions, through NF-kB inactivation, and/or upregulating DR5 receptor (Oshima et al., 2001; Shigeno et al., 2003) . Figure 5a shows that IFN-b pretreatment sensitizes ME-180 cells to apoptosis by recombinant soluble TRAIL. Interestingly, the synergistic effect of IFN-b and TRAIL was greater in synchronized cells and appeared to be specifically linked to DNA synthesis alteration. Indeed, S-phase accumulation per se could not explain the increased susceptibility to TRAIL, as exogenous TRAIL affected cell survival regardless of cell cycle distribution (data not shown). We then investigated the ability of IFN-b to affect TRAIL-mediated NF-kB-binding activity (Figure 5b ). To clarify the role of NF-kB in IFN-b-induced apoptosis, we infected ME-180 cells with an adenoviral vector expressing the natural NF-kB inhibitor IKBa. IKBa overexpression was able to strongly inhibit NF-kB p50/p65 DNA binding induced by combined treatment with IFN-b and TRAIL (data not shown). Figure 5c shows that inhibition of NF-kB by IKBa overexpression reduced the apoptosis by both IFN-b and exogenous TRAIL as well as the synergism of the two factors, confirming the proapoptotic role of NF-kB activation in this cell system, according to studies performed in other epithelial cell lines (Shetty et al., 2002) . It has been shown that IFNs sensitize different cell types to TRAIL by upregulating TRAIL receptors (Sedger et al., 1999; Meng and El-Deiry, 2001; Shigeno et al., 2003) . Interestingly, this induction appears to be an indirect effect of IFN treatment since it emerges only at late times. In ME-180 cells, we observed that TRAIL-R2 receptor expression was upregulated by IFN-b at both mRNA and protein level, overall in synchronized cells (Figure 5d and e). It must be noted that the greater induction of TRAIL-R2 in cells accumulated in the S-phase did not reflect a higher overall IFN-b responsiveness of ME-180 cells during the S-phase. Indeed, several IFN-b target genes were induced at comparable levels in asynchronous and synchronized cells, as evaluated by Western blot (data not shown).
Since TRAIL-R2 as well as TRAIL are potential targets of NF-kB, we asked whether IFN-b-potentiated NF-kB activity, as a consequence of the S-phase alteration, could promote apoptosis through TRAIL-R2 upregulation and/or TRAIL autocrine loop. Results obtained in ME-180 cells overexpressing IKBa indicated that NF-kB inactivation did not affect either TRAIL-R2 or TRAIL expression (data not shown).
Altogether, these findings suggest that the IFN-binduced S-phase deregulation can modulate TRAIL signaling by increasing NF-kB activity and TRAIL-R2 expression, probably through independent pathways. Moreover, the observed NF-kB induction does not appear to be involved in the regulation of TRAIL expression.
TRAIL-dependent apoptotic pathways differ in the requirement of caspase activation
Engagement of the death receptors TRAIL-R1 and TRAIL-R2 by TRAIL results in the activation of caspase-8, which triggers cell death, either by directly activating downstream effector caspases or by cleaving Bid, which promotes the mitochondrial death pathway (Baetu and Hiscott, 2002) . To study mitochondrial membrane perturbation and its relationship with 
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Discussion
Here, we describe the antitumor action of IFN-b in cervical carcinoma cells by linking the effects on cell cycle progression and programmed cell death. Understanding this linkage appears to be of primary importance in the search for new therapeutic strategies to circumvent cancer disease progression or improve clinical outcome.
We previously reported that IFN-b is able to induce a significant lengthening of the cell cycle S-phase and apoptotic cell death in squamous cervical carcinoma ME-180 cells (Giandomenico et al., 1998; Vannucchi et al., 2000) . The present data show that the apoptosis is a consequence of the S-phase lengthening imposed by IFN-b. We observed that cell cycle arrest by the DNA synthesis inhibitor aphidicolin, preventing S-phase progression, blocks IFN-b-induced apoptosis, whereas cell synchronization causes in IFN-b-treated populations a very high accumulation of apoptotic cells. It must be noted that even if apoptosis induction emerges as a secondary event, it significantly affects cell survival because cell cycle progression is strongly inhibited. Thus, the characterization of IFN-b-induced death signaling is important to potentiate apoptosis induction for therapeutic purposes.
It is increasingly clear that cell cycle response to specific cell growth inhibitors is largely dependent on the cellular system. ME-180 cells express E6 and E7 HPV oncoproteins, which inhibit p53 and pRb tumor suppressor proteins, respectively. We have demonstrated that the IFN-b-induced DNA synthesis slowing in ME-180 cells is mediated by the upregulation of the NBs-associated PML protein (Vannucchi et al., 2000) . Since PML can induce apoptosis via p53 (Fogal et al., 2000) , we asked whether PML could mediate the IFN-b effect on cell cycle and apoptosis of ME-180 cells by inducing p53 activity, in spite of the inhibition exerted by the viral oncoprotein E6. We found that p53 transcriptional function is not principally involved in the observed cell cycle alteration and apoptosis. In fact, ME-180 clonal populations overexpressing the dominant-negative protein p53His175 did not differ from parental cells in the response to IFN-b. Our data show that the IFN-b-induced apoptosis in ME-180 cells is specifically mediated by TRAIL. Indeed, a soluble TRAIL receptor 2 (DR5) inhibited the apoptosis due to IFN-b. Actually, IFN-b appears to activate TRAIL death pathway by upregulating TRAIL expression and increasing cell sensitivity to TRAIL. We found that both phenomena are linked to the S-phase deregulation imposed by IFN-b, providing a molecular basis for the correlation between cell cycle alteration and apoptosis. TRAIL mRNA was induced as early as 6 h upon IFN-b treatment and increased with time in asynchronous as well as in synchronized cells. Since TRAIL promoter contains IFN-stimulated response elements and IFN-g activated sequence (Gong and Almasan, 2000; Wang et al., 2000; Sato et al., 2001) , it is conceivable that the early increase in TRAIL mRNA was the result of a direct transcriptional activation by IFN-b, consistently with numerous evidences (ChawlaSarkar et al., 2001; Chen et al., 2001; Toomey et al., 2001) . Surprisingly, the induction of surface TRAIL protein by IFN-b was higher in synchronized cells, accumulated in the lengthened S phase. Interestingly, we found that surface TRAIL basal levels were cell cycle dependent, being higher in S and G2 phases. This indicated that IFN-b can increase TRAIL expression in ME-180 cells, both directly by upregulating its mRNA and indirectly augmenting surface protein levels as a consequence of the S-phase cell accumulation. It has been shown that type I IFN, besides upregulating TRAIL, can also sensitize different cell types to TRAIL-induced apoptosis (Oshima et al., 2001; Chawla-Sarkar et al., 2002; Shigeno et al., 2003) . In ME-180 cells, IFN-b potentiated significantly TRAILinduced apoptosis overall in synchronized cells, accumulated in the altered S-phase. The increased sensitivity to TRAIL was not simply due to a major number of cells in the S-phase, because the apoptotic response to TRAIL was independent of cell cycle distribution. Thus, sensitization to TRAIL in ME-180 cells was a specific effect of the IFN-b-induced S-phase deregulation.
It is well known that besides caspase cascade, TRAIL can activate NF-kB (Hu et al., 1999; Muhlenbeck et al., 2000) . However, the biological significance and the identity of the NF-kB complexes involved in TRAILdependent NF-kB activation are still controversial. In different cell types, NF-kB activation upregulates the expression of survival factors such as members of the inhibitor of the apoptosis family and Bcl-xL (Wang et al., 1998; Chen et al., 2000) . In contrast, TRAILdependent NF-kB activation appears to trigger apoptosis rather than survival in epithelial cell lines and T cells (Baetu et al., 2001; Shetty et al., 2002) . Another aspect to clarify is how type I IFN can increase cell susceptibility to TRAIL by affecting NF-kB activity. It has been reported that type I IFN is able to sensitize human hepatoma cells to TRAIL by repressing TRAILinduced cytoprotective NF-kB activity, through inhibition of p50/p65 NF-kB-DNA binding (Shigeno et al., 2003) . Surprisingly, we found that IFN-b can modulate TRAIL signaling by increasing TRAIL-dependent NFkB activity. In particular, the synergistic action of IFN-b, higher in synchronized cells, was associated with an increase of the NF-kB p50/p65 DNA binding induced by exogenous soluble TRAIL. Inhibition of this activity, by overexpressing the natural NF-kB inhibitor IkB-a, significantly decreased the ability of IFN-b to induce apoptosis and cell sensitivity to exogenous TRAIL. This result supports the correlation between S-phase alteration and apoptosis induction by IFN-b, and suggests that in our cell system, according to what was observed in other epithelial-derived cell lines (Shetty et al., 2002) , TRAIL-induced NF-kB p50/p65 activity contributes to apoptosis rather than cell survival.
Increased sensitivity to TRAIL by IFNs has also been related to the upregulation of TRAIL-R2 death receptor in different cell types, probably through indirect mechanisms (Sedger et al., 1999; Meng and El-Deiry, 2001; Shigeno et al., 2003) . We found that IFN-b affected TRAIL death signaling in ME-180 cells by inducing TRAIL-R2 expression to a major extent in synchronized cells accumulated in the altered S-phase.
These data indicated that TRAIL-R2 upregulation could be caused by the DNA synthesis alteration, according to the observation that genotoxic agents increase TRAIL death receptor expression (Gibson et al., 2000; Shin et al., 2002) .
Although both TRAIL and DR5 can be regulated by NF-kB (Baetu et al., 2001; Shetty et al., 2002) , our results, obtained by using IKBa to impair NF-kB activity, suggest that in our cell system targets other than TRAIL and DR5 are involved in the proapoptotic activity of NF-kB.
On the other hand, DR5 upregulation by type I IFN appears to be independent of NF-kB in human hepatoma cells (Shigeno et al., 2003) .
Thus, we have identified two possibly independent proapoptotic pathways involving NF-kB and TRAIL-R2 receptor, respectively, which provide a molecular basis to link IFN-b-induced S-phase deregulation and apoptosis induction.
The evidence that IFN-b can significantly affect the signaling activated by TRAIL emerged also by the analysis of the death pathway. In general, engagement of the death receptors TRAIL-R1 and TRAIL-R2 by TRAIL results in the recruitment and activation of caspase-8, which promotes apoptosis, either by directly activating downstream effector caspases or by cleaving Bid, which in turn triggers the mitochondrial death pathway (Baetu and Hiscott, 2002) . According to this, TRAIL-dependent caspase activation by IFN-b determined in ME-180 cells a significant decrease in mitochondrial membrane potential and resulted in being responsible for cell detachment and DNA condensation. In contrast, PS externalization appeared to be largely independent of caspase activity. Actually, it has been demonstrated that TNFR family members can trigger cell death via a caspase-independent pathway regardless of the presence of a death domain in the receptor (Wilson and Browning, 2002) . Thus, it is conceivable that, due to IFN-b activity, TRAIL is able to engage two or more prodeath mechanisms, one of which could cause PS externalization in a caspase-independent manner.
Altogether, our data demonstrate that IFN-b-induced apoptosis is a consequence of the S-phase alteration and occurs, independently of p53, through pathways activated by TRAIL, in a manner strictly related to the cellular context. Unlike FasL and TNF, which are toxic to liver cells and cannot be used therapeutically, TRAIL has been proposed as a new molecular-based treatment of cancer since it appears to target tumor cells without affecting surrounding health tissue. TRAIL-induced apoptosis is independent of p53 status, which makes it potentially effective against tumors that are resistant to chemotherapy (Sheikh et al., 1998; El-Deiry, 2001 ). In several tumor types, including colon, breast, glioma and urinary bladder carcinoma, as well as hepatoma, melanoma and leukemia, the activity of TRAIL was enhanced by IFNs, chemotherapy or radiation therapy, in vitro and in vivo (Ashkenazi et al., 1999; Chawla-Sarkar et al., 2002; Shigeno et al., 2003; Younes and Kadin, 2003) .
Our observation that IFN-b increases cell sensitivity to TRAIL by deregulating the S-phase indicates that combined use of IFN and TRAIL may have therapeutic potential in the treatment of human cervical cancer by increasing apoptotic cell death. Moreover, it is conceivable that other agents, able to potentiate the S-phase deregulation imposed by IFN-b, that is, retinoic acid (Vannucchi et al., 2000) , could also have a synergistic effect in combined therapy of cervical carcinoma.
Finally, we have identified in ME-180 cells treated with type I IFN a useful model to characterize still unknown TRAIL-dependent death signals and clarify their role in cell commitment to die.
Materials and methods
Cell culture and treatments
The human epidermoid cervical carcinoma cell line ME-180 was maintained in McCoy's medium (10% FBS). Human recombinant IFN-b (Rebif; 3 Â 10 8 IU/mg of protein; AresSerono) was added to the medium at the concentration of 200 IU/ml.
Synchronization in the early S-phase was obtained by treating cells with the DNA polymerase a inhibitor aphidicolin (1 mg/ml) for 16 h. When a prolonged cell cycle arrest was required, the same amount of aphidicolin was added again to the cultures after 24 h. To block caspase activity, the broadspectrum caspase inhibitor Boc-D-fmk (100 mM) was added to cultures 15 min before IFN-b treatment; for the time point of 48 h, the caspase inhibitor was added again after 24 h. The level of caspase inhibition was measured at cellular level by using a fluorochrome-conjugated in situ marker of caspase activity (10 mM, CaspACEt FITC-VAD-FMK, Promega). The reduction in cell number with caspase activity was X70%. The human recombinant fusion proteins rhsKillerTRAILt (100 ng/ml) and rhTRAIL-R2:Fc (1 mg/ml) (Alexis) were used for the functional analysis of the TRAIL system. The neutralizing anti-Fas mAb (clone ZB4, Upstate Biotechnology) was used at the concentration of 5 mg/ml. In 48 h blocking experiments, the same amount of TRAIL-R2:Fc and neutralizing anti-Fas mAb were added again after 24 h.
Flow cytometry
For cell cycle analysis, cells were fixed in 70% ice-cold ethanol for at least 30 min. DNA staining was performed by incubating cells in PBS containing 0.18 mg/ml propidium iodide (PI) and 0.4 mg/ml DNase-free RNase (type 1-A). To relieve TRAIL-R2 expression, cells were incubated with mIgG1 anti-TRAIL-R2 clone HS201 (Alexis) or control mIgG1, followed by biotin-conjugated goat affinity-purified F(AB 0 )2 fragment to mouse IgG (ICN, Cappel) and streptavidin-FITC (Calbiochem). TRAIL surface expression was determined by incubating cells with FITC-conjugated TRAIL-R2-Fc (Alexis).
Apoptosis detection
The analysis of PS on the outer leaflet of apoptotic cell membranes was performed by using Annexin-V-Biotin (Roche) following the manufacturer's instructions. In the Annexin-V/Hoechst double assay, PS analysis was followed by cell permeabilization in 0.1% Triton X-100 solution in PBS and nuclear staining with 1 mg/ml of bisbenzimide Hoechst 33258 fluorochrome (SIGMA). Fluorescences were examined on a fluorescence microscopy.
Caspase activity was revealed at cellular level by using a fluoroisothiocyanate conjugate of the cell-permeable caspase inhibitor VAD-FMK. The CaspACEt FITC-VAD-FMK In situ Marker (10 mM, Promega) was added to cultures 20 min before the analysis. Cells were then harvested and fixed in 10% buffered formalin. Nuclei were evidenced by staining with Hoechst, the previous permeabilization being as described above.
The loss of mitochondrial membrane potential (Dc m ) was measured by using the cationic dye 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolycarbocyanine iodide (JC-1, Molecular Probes). The color of the dye changes from green to greenish orange as the mitochondrial membrane becomes more polarized. After treatments, adherent ME-180 cells were harvested, incubated in growth medium containing 10 mg/ml JC-1 for 15 min at 371C and analysed by flow cytometry.
Transfection and infection procedures
The Lp53His175SP and LxSP retroviral vectors were kindly provided by G Blandino. Recombinant retroviruses, produced by transfecting PHOENIX packaging cells, were used to infect ME-180 cells at high-viral multiplicity. At 48 h after infection, cells were cloned by limiting dilution in selection medium containing 2 mg/ml puromycin. Cell clones expressing high levels of p53His175 mutant were identified by Western blot. In the transactivation assays, selected clones were transiently transfected by electroporation with a reporter vector carrying the luciferase gene under the control of the p53-dependent intronic promoter of the mdm2 gene (kindly provided by B Vogelstein). The expression vector pRL-TK (Promega), containing the Renilla luciferase gene driven by the herpes simplex virus-thymidine kinase promoter, was cotransfected to normalize the transfection efficiency. At 24 h after transfection, cells were incubated with As 2 O 3 for 24 h to induce p53 activity. Luciferase activity was measured by using the Dual-Luciferase Reporter Assay System (Promega).
The recombinant adenovirus coding for IKBa (Ad-IKBa) and the corresponding empty vector (Ad-ctr) used for negative control were kindly provided by C Gaetano. ME-180 cells were infected at 200 PFU (1 h) and treated 24 h postinfection as described.
Macroarray and RNase protection
Total RNA was isolated from ME-180 cells through RNeasy mini column method (Qiagen). According to the manufacturer's recommendations, 32 P-labeled cDNA probes were generated by reverse transcription of 4 mg of total RNA and applied to an Atlas Human Apoptosis Array (Clontech Laboratories). Signals from autoradiograms were quantified by using specific software (AtlasImage 2.01; Clontech Laboratories).
The RNase protection assay was performed using the RiboQuant Multi-Probe RNase Protection Assay System hAPO3d (Pharmingen).
EMSA EMSA was performed as described previously (Percario et al., 1999) . Double-stranded oligonucleotides containing consensus binding site for NF-kB (AGTTGAGGGGACTTTCC CAGGC; Promega) were used as a probe. Supershift was assayed with 2 mg of specific antibody against p65 and p50 (Santa Cruz Biotechnology) prior to incubation with the labeled oligonucleotide.
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